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Abstract
Central nervous system high-grade neuroepithelial tumors with BCOR alteration (CNS
HGNET-BCOR) are a recently reported rare entity, identiﬁed as a small fraction of tumors
previously institutionally diagnosed as so-called CNS primitive neuroectodermal tumors.
Their genetic characteristic is a somatic internal tandem duplication in the 30 end of BCOR
(BCOR ITD), which has also been found in clear cell sarcomas of the kidney (CCSK) and
soft tissue undifferentiated round cell sarcomas/primitive myxoid mesenchymal tumors of
infancy (URCS/PMMTI), and these BCOR ITD-positive tumors have been reported to share
similar pathological features. In this study, we performed a clinicopathological and molecular
analysis of six cases of CNS HGNET-BCOR, and compared them with their counterparts in
the kidney and soft tissue. Although these tumors had histologically similar structural
patterns and characteristic monotonous nuclei with ﬁne chromatin, CNS HGNET-BCOR
exhibited glial cell morphology, ependymoma-like perivascular pseudorosettes and
palisading necrosis, whereas these features were not evident in CCSK or URCS/PMMTI.
Immunohistochemically, diffuse staining of Olig2 with a mixture of varying degrees of
intensity, and only focal staining of GFAP, S-100 protein and synaptophysin were observed
in CNS HGNET-BCOR, whereas these common neuroepithelial markers were negative in
CCSK and URCS/PMMTI. Therefore, although CNS HGNET-BCOR, CCSK and URCS/
PMMTI may constitute a group of BCOR ITD-positive tumors, only CNS HGNET-BCOR
has histological features suggestive of glial differentiation. In conclusion, we think CNS
HGNET-BCOR are a certain type of neuroepithelial tumor relatively close to glioma, not
CCSK or URCS/PMMTI occurring in the CNS.
INTRODUCTION
Recently, Sturm et al reported that, based on the comprehensive
(epi)genome-wide analyses, tumors previously institutionally
diagnosed as so-called central nervous system primitive neuroecto-
dermal tumors (CNS-PNET) were mostly reclassiﬁed as other well-
deﬁned tumor entities, such as high-grade gliomas with IDH1/2 or
H3F3A mutation, medulloblastomas (WNT, SHH, group 3 or group
4) or ependymomas with RELA or YAP fusion, and furthermore,
found four new, unrecognized tumor types in the remaining groups:
CNS neuroblastoma with FOXR2 activation, CNS Ewing sarcoma
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family tumor with CIC alteration, CNS high-grade neuroepithelial
tumor (HGNET) with MN1 alteration and CNS HGNET with
BCOR alteration (CNS HGNET-BCOR) (25). In the CNS
HGNET-BCOR entity, somatic internal tandem duplications
(ITD) in the 30 end (exon 15) of the BCOR gene were recurrently
identiﬁed in 14 tumors, and BCOR mRNA overexpression was
noted (25). Clinically, CNS HGNET-BCOR predominantly
affected children and occurred mostly in the supratentorial but
occasionally in the infratentorial region, and preliminary survival
data suggested poor overall survival (25). These tumors were
reported to present as well-circumscribed masses, to frequently
histologically exhibit ﬁbrillary cytoplasmic processes suggesting
glial differentiation, and to often have ependymoma-like perivas-
cular pseudorosettes (25). Immunohistochemically, the tumor cells
frequently exhibited GFAP expression, but neuronal antigen
expression was focal or absent (25).
BCOR ITD was ﬁrst described in clear cell sarcoma of the kid-
ney (CCSK) by Ueno-Yokohata et al (26). CCSK are aggressive
childhood tumors that account for 2%–5% of primary renal neo-
plasms in children (8, 10). Histologically, CCSK display various
morphological patterns; the classic appearance is composed of
monotonous round to oval cells with characteristic nuclei contain-
ing ﬁne chromatin and indistinct nucleoli, and delicate branching
vessels with a chicken-wire appearance separating the tumor cells
into nests or cords, with the less common morphologies being a
myxoid background, sclerosing stroma, acinar or rosette-like for-
mation or spindle cell cytomorphology (2). BCOR ITD has been
identiﬁed as a recurrent abnormality in approximately 85% of
CCSK (3, 14, 23, 26), and YWHAE-NUTM2 fusion has been mutu-
ally exclusively found in 9%–12% of the cases (14, 19). Both
CCSK with BCOR ITD and those with YWHAE-NUTM2 fusion
were reported to exhibit nuclear expression of BCOR (13), suggest-
ing that these different genetic abnormalities may trigger a similar
downstream pathway (12).
Soft tissue undifferentiated round cell sarcomas (URCS) are a
heterogenous group of tumors that are histologically composed of
tumor cells with monomorphous round nuclei and scant cyto-
plasm, demonstrating varying genetic abnormalities and clinical
features. Recently, BCOR ITD was identiﬁed in a subset of
URCS in infants and in nearly all so-called primitive myxoid
mesenchymal tumors of infancy (PMMTI) (12, 24). Moreover,
URCS/PMMTI with BCOR ITD and URCS with other BCOR-
related fusions or YWHAE-NUTM2 fusion have been found to
share similar histological features and nuclear expression of
BCOR with CCSK (12, 13). Recently, Chiang et al reported that
a high-grade endometrial stromal sarcoma in a 25-year-old female
harbored BCOR ITD, and the tumor was histologically similar
with high-grade endometrial stromal sarcomas with YWHAE-
NUTM2 fusion (6).
Since Sturm et al ﬁrst introduced CNS HGNET-BCOR, only
ﬁve cases have been reported (1, 16, 20). Appay R et al examined
three cases of cerebellar HGNET-BCOR, and noted the possibility
that these tumors represent a local variant of the same entity as
CCSK and URCS/PMMTI with BCOR ITD because they all shared
pathological features, BCOR ITD and BCOR nuclear immunoreac-
tivity (1). In the current report, we performed a clinicopathological
and molecular analysis of six new cases of CNS HGNET-BCOR
and compared them with their counterparts in the kidney and soft
tissue to better characterize this emerging entity.
MATERIALS AND METHODS
Tumor samples
Six cases of HGNET-BCOR were collected for this study (Table 1).
Four and two cases were from the consultation ﬁles of the authors,
JH and SN, respectively. We searched the consultation archives for
“unclassiﬁed high-grade neuroepithelial tumors” composed of
tumor cells with monotonous round to oval nuclei containing ﬁne
chromatin, a characteristic feature of CCSK and URCS/PMMTI
with BCOR ITD reported (12), showing a solid growth pattern. We
found six such cases and analyzed them for BCOR ITD, and the
ITD was detected in all six cases (for details see “RESULTS”). For
reference, ﬁve CCSK cases and one URCS/PMMTI case were col-
lected from the pathology archives of the Department of Anatomic
Pathology, Kyushu University, and Department of Clinical Labora-
tory, Gunma Children’s Medical Center, respectively. Sections for
histological and genetic analyses were prepared from formalin-ﬁxed
parafﬁn-embedded (FFPE) tissue specimens. This study was con-
ducted in accordance with the Gunma University Ethical
Committee.
Conventional histological analysis
Three-micrometer-thick tissue sections were cut and stained with
hematoxylin and eosin. Immunohistochemical staining was per-
formed on FFPE tissue sections. Primary antibodies directed
against the following antigens were applied: BCOR (C-10; 1:100;
Santa Cruz Biotechnology, Dallas, TX, USA), vimentin (V9;
1:200; Dako, Glostrup, Denmark), glial ﬁbrillary acidic protein
(GFAP) (1:5000) (18), Olig2 (1:5000) (27), S-100 protein
(1:10000) (18), synaptophysin (27G12; 1:200; Leica Microsystems,
Newcastle, UK), neuroﬁlament protein (RMdO-20; 1:100; Thermo
Fisher Scientiﬁc, MA, USA), epithelial membrane antigen (EMA)
(E29; 1:100; Dako), BAF47/INI1 (BAF47; 1:100; BD Bioscience,
San Jose, CA, USA), BRG1 (polyclonal; 1:1000; Millipore, Teme-
cula, CA, USA) and Ki-67 (MIB-1; 1:100; Dako). For coloration, a
commercially available biotin-streptavidin immunoperoxidase kit
(Histoﬁne, Nichirei, Tokyo, Japan) and diaminobenzidine were
used. For BCOR staining, spermatogonia in the seminiferous
tubules of the normal testis were used as positive controls (13).
For BCOR, vimentin, GFAP, Olig2, S-100 protein, synaptophy-
sin and neuroﬁlament protein, the intensity of the staining was
graded as negative, weak, moderate or strong, and the extent was
scored as follows: 2, completely negative; 11, <10% of tumor
cells are positive; 21, 10%–50% of tumor cells are positive; 31,
>50% of tumor cells are positive.
PCR and direct DNA sequencing
of BCOR exon 15
Genomic DNA was extracted from FFPE tissue sections as previ-
ously described (11), and was ampliﬁed and sequenced using previ-
ously described primer sets for detecting BCOR ITD (12). PCR
products were analyzed by agarose gel electrophoresis, and were
then sequenced on a 3130xl Genetic Analyzer (Applied Biosys-
tems, Foster City, CA, USA) with the Big Dye Terminator v.1.1
Cycle Sequencing Kit (Applied Biosystems) following standard
procedures.
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RESULTS
Clinical findings
Relevant clinical data are summarized in Table 1. The age at
diagnosis ranged between 7 months and 22-year old. Of ﬁve
cases with available clinical data, three cases underwent total
tumor resection and intensive adjuvant chemoradiotherapies, fol-
lowing relatively favorable outcome over 2 years (cases 2, 3 and
5), whereas the patients in the remaining two cases died within 2
months because of the massive tumor regrowth after surgery and
patient refusal of additional therapies (cases 1 and 6). In addition
to local recurrence, subcutaneous seeding of the tumor was
observed in case 2.
Imaging features
Magnetic resonance images of ﬁve cases (cases 1, 2, 3, 5 and 6)
were studied. All ﬁve tumors exhibited similar radiographic
ﬁndings. They appeared to be well-demarcated masses located
in the superﬁcial portion of the cerebral or cerebellar hemi-
spheres. The tumors were hypo-intense on T1-weighted images
(Figure 1A,D), hyper-intense on T2-weighted images (Figure
1B,E) and hyper-intense on diffusion-weighted images (Figure
1F). Varying degrees of heterogenous enhancement was
observed after gadolinium injection (Figure 1C). Three of ﬁve
possessed cystic components (cases 1, 3 and 5), and intratumoral
hemorrhage as evidenced by T2 star sequences was observed in
two cases (cases 1 and 3).
Histopathological findings
The most predominant pattern in CNS HGNET-BCOR was the
compact growth of stellate tumor cells with delicate branching ves-
sels demonstrating a chicken-wire appearance, composing most of
cases 2–4 and a part of case 5 (Figure 2A,H,I). A solid growth of
spindle-shaped cells in bundles with the same vascular pattern was
commonly seen, being a predominant pattern in case 5 (Figure 2B).
All CNS HGNET-BCOR cases exhibited, in varying degrees,
microcystic formation composed of stellate cells in a myxoid and
edematous background; cases 1 and 6 were mainly composed of
this pattern (Figure 2C). Ependymoma-like perivascular pseudoro-
settes formed by the cell processes were a common ﬁnding (Figure
2D,E). Rosette-like formation containing a central area of cell proc-
esses was focally seen in cases 1, 3 and 4. A haemangiopericytoma-
like stag-horn vascular pattern was focally found in case 3. Cellular
ﬁbroblastic septa commonly described in CCSK were not observed
in any case (2). The interface between the tumor and normal brain
parenchyma was fairly sharp in case 1 (Figure 2F), whereas micro-
scopically minimal inﬁltration of isolated tumor cells was found in
case 2 (Figure 2G).
Most tumor cells were stellate-shaped with scant cytoplasm,
ﬁbrillary processes and monotonous round to oval nuclei contain-
ing ﬁne chromatin and indistinct to small nucleoli (Figure 2H). The
nuclei were less chromatic than or isochromatic to those of endo-
thelia (Figure 2H). Mild nuclear size variation was focally observed
in cases 4 and 6, and slightly prominent nucleoli were found in
some cells in cases 5 and 6 (Figure 2I). The cytoplasm was lightly
eosinophilic to amphophilic, being less eosinophilic than that of
Figure 1. Radiological images of central nervous system high-grade neu-
roepithelial tumors with BCOR alteration (CNS HGNET-BCOR); A–C: case
2, D–F: case 3. The tumors presented as similar well-demarcated masses
located in the cerebellar or cerebral hemispheres, hypo-intense on
T1-weighted images (A, D), hyper-intense on T2-weighted images (B, E),
hyper-intense on diffusion-weighted images (F) and with slight to moder-
ate contrast enhancement (C). Partial cystic changes and intratumoral
hemorrhage were also observed (D–F).
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4 Brain Pathology •• (2017) ••–••
VC 2017 International Society of Neuropathology
typical neoplastic astrocytes or ependymal cells (Figure 2H,I).
Tumor cells with small, round nuclei and clear cytoplasm resem-
bling oligodendroglioma cells or neurocytes were focally found in
case 3 (Figure 2J).
Mitotic counts ranged from 8 to 41 per 10 high-power ﬁelds
(Table 2). Necrosis was observed in four cases, of which palisading
necrosis was identiﬁed in cases 1, 2 and 4 (Figure 2K). Microvas-
cular proliferation was not observed in any case.
Figure 2. Microscopic appearance of CNS HGNET-BCOR. A. A
compact growth of tumor cells with delicate branching vessels
exhibiting a chicken-wire appearance (case 3). B. A solid growth of
spindle-shaped cells in bundles (case 5). C. Microcystic formation in a
myxoid and edematous background (case 1). D, E. Ependymoma-like
perivascular pseudorosettes in cases 2 and 3, respectively. E. A peri-
vascular anuclear zone formed by the cell processes. F. A sharp inter-
face between the tumor and normal brain parenchyma (case 1). G.
Minimal infiltration of isolated tumor cells into the surrounding brain
parenchyma (case 2). H, I. High magnification of tumor cells. H.
Tumor cells with monotonous round to oval nuclei containing fine
chromatin and indistinct to small nucleoli (case 3). I. Mild nuclear size
variation and some cells with slightly prominent nucleoli (case 6). J.
Tumor cells with small, round nuclei and clear cytoplasm resembling
oligodendroglioma cells and neurocytes (case 3). K. Palisading necro-
sis (case 2). L. A recurrent tumor from subcutaneous seeding (case
2). Original magnification: A, C, F, K, 3100; B, D, G, L, 3200; E, J,
3400; H, I, 3600.
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The specimen from the metastasis of case 2 exhibited a solid
growth of monotonous round, oval and polygonal cells with deli-
cate branching vessels with a chicken-wire appearance separating
the tumor cells into nests (Figure 2L). Stellate-shaped tumor cells
with ﬁbrillary processes and ependymoma-like perivascular pseu-
dorosettes observed in the primary intracerebellar tumor were not
evident.
The immunohistochemical ﬁndings in CNS HGNET-BCOR are
summarized in Table 2. Most cases of CNS HGNET-BCOR exhib-
ited diffuse and strong staining with vimentin (Figure 3A). GFAP
immunoreactivity was identiﬁed in the cytoplasm and ﬁbrillary
processes of a small number of tumor cells (Figure 3B), but not in
anuclear zones of ependymoma-like perivascular pseudorosettes.
Positivity for S-100 protein was almost the same as that for GFAP
(Figure 3C). All cases were immunopositive for Olig2, diffusely in
most cases, with a mixure of varying degrees of intensity (Figure
3D). Immunoreactivity for synaptophysin was detected in scattered
tumor cells in 3/6 cases (Figure 3E), whereas more diffuse expres-
sion of neuroﬁlament protein was observed (Figure 3F). The reac-
tivity for synaptophysin was not evident in the rosette-like
structures. Ring-like and dot-like patterns of cytoplasmic EMA
positivity were not observed in any case. Diffuse nuclear immuno-
reactivity for BCOR was detected in all cases (Figure 3G,H). The
recurrent tumor of subcutaneous seeding in case 2 also exhibited
diffuse BCOR expression. Nuclear BCOR expression was also
found in the external granular layer cells in the adjacent cerebellum
of case 5, but not in the internal granular layer cells (Figure 3I).
Expression of INI1/BRG1 was retained in all cases. MIB-1 labeling
indices ranged from 12% to 52.7%.
CCSK cases were mostly composed of round, oval and polygo-
nal tumor cells with arborizing capillary vasculature separating the
tumor cells into nests or cords (Figure 4A). Stromal sclerosis and
hyalinosis, and microcystic changes were focally observed. URCS/
PMMTI was composed of stellate tumor cells with microcystic for-
mation in a myxoid background (Figure 4B). Five CCSK cases and
URCS/PMMTI demonstrated diffuse BCOR expression (Figure
4C,D) and no reactivity for common glial antigens (GFAP, S-100
protein and Olig2) or synaptophysin; however, focal to diffuse
expression of neuroﬁlament protein was observed in all tumors
(Figure 4E,F).
PCR and direct DNA sequencing of BCOR
exon 15
BCOR ITD in exon 15 was conﬁrmed in all six CNS HGNET-
BCOR, ﬁve CCSK and one URCS/PMMTI by PCR and direct
DNA sequencing, as shown in Figure 5. The duplicated sequences
(with an insertion of 1 or 2 bp in CNS HGNET-BCOR cases 2–4
and CCSK 1) were in frame, and varied in size (90 to 114 bp),
encompassing a previously reported minimally duplicated region
(p.D1725 to p.L1737) (F,I).
DISCUSSION
Among BCOR ITD-positive tumors in the CNS, kidney and soft
tissue, we here demonstrated that only CNS HGNET-BCOR exhib-
ited neuroepithelial differentiation. Histologically, most tumor cells
of CNS HGNET-BCOR exhibited glial morphology as stellate-
shaped cells with ﬁbrillary processes (Figure 2H,I). Ependymoma-T
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like perivascular pseudorosettes and palisading necrosis, the latter
being characteristic of high-grade gliomas, such as glioblastomas
and anaplastic ependymomas, were features of glial differentiation
as well, which have not been reported in CCSK or URCS/PMMTI
(Figure 2D,E,K). Although glial differentiation was not strongly
supported by focal immunohistochemistry for GFAP, and S-100
protein (Table 2, Figure 3B,C), diffuse staining of Olig2 with a
mixture of varying degrees of intensity was notable (Figure 3D,
Table 2). Olig2 is a transcription factor required for oligodendro-
cyte and motor neuron development, and is commonly immunore-
active not only in glial tumors but also in glioneuronal tumors with
oligodendrocyte-like cells (dysembryoplastic neuroepithelial
tumors, rosette-forming glioneuronal tumors, papillary glioneuronal
tumors and diffuse leptomeningeal glioneuronal tumors) (17, 21,
27) and CNS neuroblastoma with FOXR2 activation reported by
Sturm et al (25). Patchy Olig2 staining has been noted in CNS
HGNET-BCOR in a previous study (16). URCS/PMMTI in this
study was composed of stellate tumor cells somewhat resembling
neoplastic glial cells (Figure 4D); however, immunohistochemical
evidence of glial differentiation was not evident. Neuronal markers,
synaptophysin and neuroﬁlament protein, were focally to diffusely
positive in CNS HGNET-BCOR, whereas tumor cells with small,
round nuclei and clear cytoplasm resembling neurocytes and
rosette-like formations were negative for synaptophysin, suggesting
that the cytomorphology and structure were not associated with
neuronal differentiation. URCS/PMMTI and CCSK cases were
focally to diffusely positive for neuroﬁlament protein (Figure
4C,F), but they were negative for synaptophysin; the signiﬁcance
of neuroﬁlament protein reactivity in these BCOR ITD-positive
tumors is unknown, and the possibility of cross-reaction with other
proteins cannot be ruled out.
Clinicopathologically, CNS HGNET-BCOR may be overlooked
and misdiagnosed as anaplastic ependymomas, glioblastomas,
medulloblastomas or CNS embryonal tumors, NOS. However,
Figure 3. Immunohistochemistry of CNS HGNET-BCOR. A. Diffuse
and strong positivity for vimentin (case 1). B. Patchy positivity for
GFAP in the cytoplasm and fibrillary processes of tumor cells (case 1).
C. Patchy positivity for S-100 protein in the cytoplasm and fibrillary
processes of tumor cells (case 1). D. Diffuse nuclear immunoreactiv-
ity for Olig2 with a mixture of varying degrees of intensity (case 3). E.
Scattered immunoreactivity for synaptophysin (case 1). F. Diffuse
immunopositivity for neurofilament protein (case 1). G. Diffuse
nuclear BCOR staining (case 3). H. BCOR expression highlighted iso-
lated tumor cells infiltrating into the surrounding brain parenchyma
(same area as Fig 2G; case 2). Nuclear BCOR immunopositivity was
observed in the external granular layer cells in the cerebellum, but
was absent in the internal granular layer cells I. Original magnification:
A–C, E–I, 3200; D, I inset, 3400.
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looking at the characteristic features of the nuclei is the most help-
ful clue in considering CNS HGNET-BCOR and ruling out these
differential diagnoses exhibiting more hyperchromatic nuclei. More
speciﬁcally, from our observations along with previous ﬁndings,
CNS HGNET-BCOR often had ependymoma-like perivascular
pseudorosettes and focal GFAP immunoreactivity; however, ring-
like and dot-like patterns of cytoplasmic EMA positivity and peri-
vascular cytoplasmic processes with GFAP immunostaining char-
acteristic of ependymomas were not observed. Contrary with
common glioblastomas, CNS HGNET-BCOR lacked nuclear pleo-
morphism and a diffusely inﬁltrative growth pattern, and cytologi-
cal and immunohistochemical evidence of glial differentiation were
weaker. CNS HGNET-BCOR often occurred in the cerebellum
(16/25, 56%) (Supporting Information Table S1); therefore, medul-
loblastomas, as well as ependymomas, were considered. Unlike
CNS embryonal tumors, such as medulloblastomas, the typical
embryonal morphology—a highly cellular, poorly differentiated,
hyperchromatic and mitotically active histological appearance remi-
niscent of the developing embryonic nervous system—was not
observed, and neuronal differentiation was not evident in CNS
HGNET-BCOR.
Santiago et al noted similarities between BCOR ITD-positive
tumors and malignant rhabdoid tumors (MRT) with INI1/BRG1
deﬁciency: similar morphological features among each tumor
group, tumor locations in the CNS, soft tissue and kidney, and age
distribution with most occurring in infants (24). However, unlike
extra-CNS MRT, CNS MRT, that is, atypical teratoid/rhabdoid
tumors (AT/RT), are usually not composed solely or even largely
of rhabdoid cells, and their typical histology is a jumbled appear-
ance created by epithelioid tumor cells with variability of
Figure 4. Histological and immunohistochemical findings of clear cell
sarcomas of the kidney (CCSK) and undifferentiated round cell
sarcomas/primitive myxoid mesenchymal tumors of infancy (URCS/
PMMTI) (A, C, E: CCSK, B, D, F: URCS/PMMTI). A. The classic
pattern of CCSK composed of round, oval and polygonal cells, and
arborizing capillary vasculature. B. URCS/PMMTI case composed of
stellate tumor cells with microcystic formation in a myxoid
background. C, D. Diffuse nuclear immunoreactivity for BCOR. E.
Focal immunopositivity for neurofilament protein in CCSK. F. Diffuse
immunopositivity for neurofilament protein in URCS/PMMTI. Original
magnification: A–F, 3200.
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cytoplasmic features—scant, eosinophilic, pale, clear or vacuo-
lated—with the presence of rhabdoid cells (5, 22). Therefore,
BCOR ITD-positive tumors and MRT are more similar in that,
among each tumor group, CNS tumors exhibit unique histological
features. From a genetic standpoint, soft tissue MRT have a higher
incidence of homozygous deletion of the INI gene than AT/RT and
renal MRT, and the mutation hotspots in the gene are exons 5 and
9 in AT/RT, whereas mutations in exon 2 are common in renal
MRT (4, 9). As for BCOR ITD-positive tumors, although the mini-
mally duplicated region (p.D1725 to p.L1737) were common, the
altered amino acid sequence pattern found in cases 2–4, combined
with previous studies, has been observed in 4 of 25 (16%) CNS
HGNET-BCOR, which has not been seen so far in CCSK or
URCS/PMMTI, and duplicated regions extending toward the N-
end from p.Asp1712 were more common in CNS HGNET-BCOR
(Figure 5, Supporting Information Fig. S1). However, the numbers
of reported CNS HGNET-BCOR and URCS/PMMTI are lower
than that of CCSK (176 cases) (3, 12, 14, 15, 23, 26).
Case 2 exhibited subcutaneous seeding 16 months after the ﬁrst
operation (Table 1). In the resected metastasis, tumor cells lost
ﬁbrillary cytoplasmic processes, and ependymoma-like perivascular
pseudorosettes and expression of glial markers observed in the pri-
mary tumor were not evident (Figure 2D,L, Table 2). Moreover, in
a case of CNS HGNET-BCOR reported by Paret et al, three inocu-
lation metastases developed at the skullcap, and the metastatic
tumor lost the perivascular pseudorosettes observed in the primary
tumor. Chemotherapy and radiotherapy performed after the ﬁrst
surgery may be responsible for these morphological and phenotypi-
cal changes; however, the possibility of effects of intracranial envi-
ronment on neuroepithelial differentiation of the tumors cannot be
ruled out.
BCOR immunohistochemical expression has been tested in nor-
mal tissues including the spleen, placenta, kidney, colon, liver,
skin, pancreas, testis, lung and brain (1, 13), and only spermatogo-
nia in the seminiferous tubules of the normal testis were found to
exhibit distinct nuclear staining (13). In this study, using the same
anti-BCOR monoclonal antibody, we found nuclear BCOR expres-
sion in the external granular layer cells in the adjacent cerebellum
of case 5, but not in the internal granular layer cells, which was
conﬁrmed by staining of other unrelated surgical specimens con-
taining the normal cerebellar external granular layer (Figure 3I).
The speciﬁcity of immunohistochemical nuclear expression of
BCOR in other CNS tumors, especially desmoplastic/nodular
medulloblastomas and medulloblastomas with extensive nodularity,
whose development is thought to be associated with the cerebellar
external granular layer (7), needs to be investigated.
A nosological issue is how CNS HGNET-BCOR should be clas-
siﬁed in the current World Health Organization (WHO) scheme of
CNS tumors. Although the age distribution is similar with that of
the category of “embryonal tumors,” the typical embryonal
Figure 5. BCOR exon 15 aberrations in BCOR ITD-positive tumors.
A. An example of the duplicated coding sequence of CNS HGNET-
BCOR in case 3. The 2-bp insertion and 88-bp tandem duplication are
illustrated. The nucleotide position is relative to the sequence used as
the reference (NM_001123385.1). B. Predicted protein sequences of
duplicated regions and genetic changes in the CNS HGNET, CCSK
and URCS/PMMTI. At the top, the wild-type BCOR amino acid
sequence from positions 1695 to 1755 is presented (NP_001116857).
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morphology and evident neuronal differentiation were not
observed; therefore, we believe that CNS HGNET-BCOR do not
belong in “embryonal tumors.” Although their counterparts in the
kidney and soft tissue are classiﬁed as “sarcomas,” CNS HGNET-
BCOR exhibited cytological and immunohistochemical evidence
of neuroepithelial differentiation, thus CNS HGNET-BCOR do not
ﬁt in the category of “mesenchymal, non-meningothelial tumors,”
either. A new category, in which CNS HGNET-BCOR will be clas-
siﬁed, may be established in the next WHO scheme of CNS
tumors. However, given the small number of cases examined in the
current study, further clinicopathological and genetic analyses on
more cases are needed.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Figure S1. Diagram of inferred BCOR protein sequences from
BCOR ITD-positive tumors. The dataset was composed of 204
BCOR ITD-positive tumors from 11 publications and our cohort
(6 CNS HGNET, 5 CCSK and 1 URCS/PMMTI). The frequent
duplication patterns in each tumor type are expressed as percen-
tages. Arrowhead indicates p.Asp1712.
*Duplication patterns found only in CNS HGNET-BCOR
Table S1. Comparative clinical features of BCOR ITD-positive
tumors.
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